S. aureus bacteraemia surveillance quarterly report: October-December 2010

This quarterly report provides epidemiological data onS. aureusin Northern Ireland, including overall infectionfigures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.

Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus.

The increased incidence over the past decade of bloodstream infections (BSIs) caused by gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus, highlights the critical need for a consistent approach to therapy. However, there is currently no international consensus on the diagnosis and management of gram-positive BSIs. The Clinical Consensus Conference on Gram-Positive Bloodstream Infections was convened as a session at the 9th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections held in 2007. Participants discussed various aspects of the practical treatment of patients who present with gram-positive BSI, including therapeutic options for patients with BSIs of undefined origin, the selection of appropriate empirical therapy, and treatment of complicated and uncomplicated BSIs. The opinions of participants about these key issues are reflected in this article.

Propolis: anti-Staphylococcus aureus activity and synergism with antimicrobial drugs

Propolis is a natural resinous substance collected by bees from tree exudates and secretions. Its antimicrobial activity has been investigated and inhibitory action on Staphylococcus aureus growth was evaluated. The in vitro synergism between ethanolic extract of propolis (EEP) and antimicrobial drugs by two susceptibility tests (Kirby and Bauer and E-Test) on 25 S. aureus strains was evaluated. Petri dishes with sub-inhibitory concentrations of EEP were incubated with 13 drugs using Kirby and Bauer method and synergism between EEP and five drugs [choramphenicol (CLO), gentamicin (GEN), netilmicin (NET), tetracycline (TET), and vancomycin (VAN)] was observed. Nine drugs were assayed by the E-test method and five of them exhibited a synergism [CLO, GEN, NET, TET, and clindamycin (CLI)]. The results demonstrated the synergism between EEP and antimicrobial drugs, especially those agents that interfere on bacterial protein synthesis.

Application of molecular techniques in the study of Staphylococcus aureus clonal evolution - A Review

Staphylococcus aureus is an important agent of healthcare-associated and community-acquired infections. A major characteristic of this microorganism is the ability to develop resistance to antimicrobial agents. Several molecular techniques have been applied for the characterization of S. aureus in epidemiological studies. In the present review, we discuss the application of molecular techniques for typing S. aureus strains and describe the nomenclature and evolution of epidemic clones of this important pathogen.

S. aureus bacteraemia surveillance quarterly report: January-March 2011

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.

Synergism between plant extract and antimicrobial drugs used on Staphylococcus aureus diseases

Searches for substances with antimicrobial activity are frequent, and medicinal plants have been considered interesting by some researchers since they are frequently used in popular medicine as remedies for many infectious diseases. The aim of this study was to verify the synergism between 13 antimicrobial drugs and 8 plant extracts - "guaco" (Mikania glomerata), guava (Psidium guajava), clove (Syzygium aromaticum), garlic (Allium sativum), lemongrass (Cymbopogon citratus), ginger (Zingiber officinale), "carqueja" (Baccharis trimera), and mint (Mentha piperita) - against Staphylococcus aureus strains, and for this purpose, the disk method was the antimicrobial susceptibility test performed. Petri dishes were prepared with or without dilution of plant extracts at sub-inhibitory concentrations in Mueller-Hinton Agar (MHA), and the inhibitory zones were recorded in millimeters. In vitro anti-Staphylococcus aureus activities of the extracts were confirmed, and synergism was verified for all the extracts; clove, guava, and lemongrass presented the highest synergism rate with antimicrobial drugs, while ginger and garlic showed limited synergistic capacity.

S.aureus bacteraemia surveillance quarterly report

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

S.aureus bacteraemia surveillance quarterly report: July - September 2011

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

S.aureus bacteraemia surveillance quarterly report: October - December 2011

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

S.aureus bacteraemia surveillance quarterly report: January - March 2012

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

S.aureus bacteraemia surveillance quarterly report: October - December 2012

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland

S. aureus surveillance report quarter ending 1 April 2013 to 30 June 2013

S. aureus surveillance report quarter ending 1 April 2013 to 30 June 2013

S. aureus bacteraemia surveillance quarterly report: October-December 2010

This quarterly report provides epidemiological data on�S. aureus�in Northern Ireland, including overall infection�figures as well as those specific to MRSA and MSSA. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.

C. difficile and S. aureus quarterly reports

C.difficle surveillance report quarter July-September 2015 .pdf C.difficle surveillance report quarter April-June 2015.pdf C.difficle surveillance report quarter January - March 2015.pdf C.difficle surveillance report quarter ending Oct - Dec 2014.pdf C.difficle surveillance report quarter ending July - Sept 2014.pdf C.difficle sureillance report quarter ending April - June 2014.pdf C.difficle surveillance report quarter endin January - March 2014.pdf C.difficle surveillance report quarter ending October to December 2013.pdf C.difficle surveillance report quarter ending 1st July 2013 to 30th September 2013.pdf C.difficle surveillance report quarter ending 1 April 2013 to 30 June 2013.pdf C.difficle Surveillance Report Quarter Ending 31st March 2013.pdf.pdf C.difficle Surveillance Report Quarter Ending 31st December 2012.pdf C.difficile Surveillance Report quarter ending 30 September 2012.pdf.pdf� C.difficile Surveillance Report quarter ending 30 June 2012.pdf C.difficile Surveillance Report quarter ending March 2012 C.difficile Surveillance Report quarter ending December 2011 C.difficile Surveillance Report quarter ending September 2011.pdf C. difficle Surveillance Report quarter ending June 2011.pdf C. difficile Surveillance Report quarter ending March 2011 (930KB).pdf CDI_Report Oct-Dec 2010_2.pdf Staphylococcus aureus S.aureus bacteraemia surveillance quart July-September 2015.pdf S.aureus surveillance report quarter April-June 2015.pdf S.aureus surveillance report quarter January - March 2015.pdf S.aureus surveillance report quarter Oct - Dec 2014.pdf S.aureus sureveillance report quarter July - Sept 2014.pdf S.aureus surveillance report quarter April - June 2014.pdf S. aureus surveillance report quarter January - March 2014.pdf S. aureus surveillance report quarter ending October to December 2013.pdf S. aureus surveillance report quarter ending 1st July 2013 to 30th September 2013.pdf S. aureus surveillance report quarter ending 1 April 2013 to 30 June 2013 S.aureus Surveillance Report Quarter Ending 31st March 2013.pdf.pdf S.aureus Surveillance Report Quarter Ending 31st December 2012.pdf S.aureus Surveillance Report quarter ending 30 September 2012.pdf.pdf S.aureus Surveillance Report quarter ending 30 June 2012.pdf S.aureus Surveillance Report quarter ending March 2012 S.aureus Surveillance Report quarter ending�December 2011 S.aureus Surveillance Report quarter ending September 2011.pdf S.aureus Surveillance Report quarter ending June 2011.pdf S.aureus Surveillance Report quarter ending March 2011 (999KB).pdf Surgical site infectionCumulative incidence of SSI within 30 days after Caesarean section, Reporting Year 2009 (post-discharge excluded) Cumulative incidence of SSI within 30 days after hip prosthesis, Reporting Year 2009 (post-discharge excluded) Cumulative incidence of SSI within 30 days after knee prosthesis, Reporting Year 2009 (post-discharge excluded) � �

C. difficile and S.aureus bacteraemia surveillance quarterly reports

Quarterly reports provide epidemiological data on�C. difficile and S. aureus�in Northern Ireland. The report highlights key points, rates, trends and statistical process control charts. The report also provides information on surveillance methods and data for each hospital and Health and Social Care Trust in Northern Ireland.Click here to see the latest reports